RxDoctor Payments Data

Mohit Nanda, MD

Retina Specialist · Charlottesville, VANPI 1750363396

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (54.0%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 92.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $17,150 and has fallen 95.8% since, to $717 in 2025. Among retina specialist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,799in general payments, 2019–2025

Across 69 payments — averaging $446.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$29K
  • Regeneron Healthcare Solutions, Inc.$812
  • Genentech USA, Inc.$341
  • Alimera Sciences, Inc.$306
  • Apellis Pharmaceuticals, Inc.$216
  • Astellas Pharma US Inc$187
  • plus $323 from 5 others

What the payments were for

  • Food & beverage$2,1837%
  • Ownership interest$11,98639%
  • Other$16,62954%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,799 in reported general payments places this provider in the 95th percentile of 41 retina specialist providers in Virginia.

See all retina specialist providers in Virginia

Medicare billing

Part B allowed, 2024
$5,639,195
Medicare patients
1,238
Services billed
80,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate74$1,721
Latanoprost74$799
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$625

Paid to pharmacies, not to this prescriber.

Other retina specialist in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →